NASDAQ: VALN
Valneva Se Stock Forecast, Predictions & Price Target

Analyst price target for VALN

Based on 3 analysts offering 12 month price targets for Valneva Se

Min Forecast
$14.00+140.96%
Avg Forecast
$15.33+163.91%
Max Forecast
$17.00+192.6%

Should I buy or sell VALN stock?

Based on 3 analysts offering ratings for Valneva Se.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VALN stock forecasts and price targets.

VALN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-08
lockedlocked$00.00+00.00%2025-04-15
lockedlocked$00.00+00.00%2025-03-24

1 of 1

Forecast return on equity

Is VALN forecast to generate an efficient return?

Company
150.04%
Industry
165.03%
Market
89.46%
VALN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VALN forecast to generate an efficient return on assets?

Company
54.53%
Industry
43.47%
VALN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VALN earnings per share forecast

What is VALN's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.56
Avg 2 year Forecast
$0.48
Avg 3 year Forecast
$1.56

VALN revenue forecast

What is VALN's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$213.7M+5.69%
Avg 2 year Forecast
$367.9M+81.92%
Avg 3 year Forecast
$482.5M+138.57%
VALN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VALN revenue growth forecast

How is VALN forecast to perform vs Biotechnology companies and vs the US market?

Company
32.25%
Industry
55.22%
Market
10.26%
VALN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VALN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VALN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VALN$5.81$15.33+163.91%Strong Buy
ORKA$12.60$35.00+177.78%Buy
ATYR$5.31$25.33+377.08%Strong Buy
FTRE$5.22$8.25+58.05%Sell
CAPR$10.25$35.00+241.46%Strong Buy

Valneva Se Stock Forecast FAQ

Is Valneva Se Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: VALN) stock is to Strong Buy VALN stock.

Out of 3 analysts, 2 (66.67%) are recommending VALN as a Strong Buy, 1 (33.33%) are recommending VALN as a Buy, 0 (0%) are recommending VALN as a Hold, 0 (0%) are recommending VALN as a Sell, and 0 (0%) are recommending VALN as a Strong Sell.

If you're new to stock investing, here's how to buy Valneva Se stock.

What is VALN's earnings growth forecast for 2025-2027?

(NASDAQ: VALN) Valneva Se's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.

Valneva Se's earnings in 2025 is -$91,350,000.On average, 1 Wall Street analyst forecast VALN's earnings for 2025 to be -$253,339,635, with the lowest VALN earnings forecast at -$253,339,635, and the highest VALN earnings forecast at -$253,339,635. On average, 1 Wall Street analyst forecast VALN's earnings for 2026 to be $77,950,657, with the lowest VALN earnings forecast at $77,950,657, and the highest VALN earnings forecast at $77,950,657.

In 2027, VALN is forecast to generate $253,339,635 in earnings, with the lowest earnings forecast at $253,339,635 and the highest earnings forecast at $253,339,635.

What is VALN's revenue growth forecast for 2025-2027?

(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 32.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.26%.

Valneva Se's revenue in 2025 is $211,429,545.On average, 1 Wall Street analysts forecast VALN's revenue for 2025 to be $34,710,777,955, with the lowest VALN revenue forecast at $34,710,777,955, and the highest VALN revenue forecast at $34,710,777,955. On average, 1 Wall Street analysts forecast VALN's revenue for 2026 to be $59,745,930,616, with the lowest VALN revenue forecast at $59,745,930,616, and the highest VALN revenue forecast at $59,745,930,616.

In 2027, VALN is forecast to generate $78,353,402,021 in revenue, with the lowest revenue forecast at $78,353,402,021 and the highest revenue forecast at $78,353,402,021.

What is VALN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: VALN) forecast ROA is 54.53%, which is higher than the forecast US Biotechnology industry average of 43.47%.

What is VALN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year VALN price target, the average VALN price target is $15.33, with the highest VALN stock price forecast at $17.00 and the lowest VALN stock price forecast at $14.00.

On average, Wall Street analysts predict that Valneva Se's share price could reach $15.33 by May 8, 2026. The average Valneva Se stock price prediction forecasts a potential upside of 163.91% from the current VALN share price of $5.81.

What is VALN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: VALN) Valneva Se's current Earnings Per Share (EPS) is -$1.27. On average, analysts forecast that VALN's EPS will be -$1.56 for 2025, with the lowest EPS forecast at -$1.56, and the highest EPS forecast at -$1.56. On average, analysts forecast that VALN's EPS will be $0.48 for 2026, with the lowest EPS forecast at $0.48, and the highest EPS forecast at $0.48. In 2027, VALN's EPS is forecast to hit $1.56 (min: $1.56, max: $1.56).

What is VALN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: VALN) forecast ROE is 150.04%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.